

---

**Isolation of human cDNA clones of *myb*-related genes, A-*myb* and B-*myb***

---

Nobuo Nomura\*, Masayoshi Takahashi<sup>1</sup>, Minami Matsui, Shunsuke Ishii<sup>2</sup>, Takayasu Date<sup>3</sup>, Shigemi Sasamoto and Ryotaro Ishizaki

---

Molecular Oncology Laboratory, Nippon Veterinary and Zootechnical College, Sakuragi, 1-10-19 Uenosakuragi, Taito-ku, Tokyo 110, <sup>1</sup>Institute of Applied Microbiology, University of Tokyo, Bunkyo-ku, Tokyo 113, <sup>2</sup>Laboratory of Physical and Chemical Research, RIKEN, 3-1-1 Koya-dai, Tsukuba, Ibaraki 305 and <sup>3</sup>Department of Biochemistry, Kanazawa Medical University, Uchinada, Ishikawa 920-02, Japan

---

Received September 15, 1988; Revised and Accepted November 8, 1988

Accession nos X13293, X13294

---

**ABSTRACT**

cDNA clones of the *myb*-related genes A-*myb* and B-*myb* were obtained by screening human cDNA libraries. The predicted open reading frame of B-*myb* could encode a protein of 700 amino acid residues. Although the C-terminal end has not been cloned yet, an almost entire coding region of A-*myb*, which is 745 amino acid long, was determined. The A-*myb* and B-*myb* proteins are highly homologous with the *myb* protein in three regions. Domain I, which is 161 amino acid long, is well conserved in the *myb* gene family. The homology between human-*myb* and A-*myb* in domain I is 90% at the amino acid level. Domain II, which is about 85 amino acid long, is less well conserved. Although it is a short stretch, domain III is found in the C-terminal region. The mRNAs of A-*myb* and B-*myb* were 5.0 and 2.6kb, respectively. The mRNA expression pattern of the *myb* gene family in various tumors is presented.

**INTRODUCTION**

The *myb* protooncogene is an evolutionarily conserved locus identified by its homology with the transforming gene v-*myb* of avian myeloblastosis virus (AMV) and avian erythroblastosis virus E26 (1-4). The products of the c-*myb* and v-*myb* genes appear to be nuclear DNA binding proteins (2,5,6,7). Recently the v-*myb* protein was shown to specifically recognize the nucleotide sequence pyAAC<sup>G</sup>/<sub>T</sub>G (8). It has been reported that c-*myb* mRNA is expressed predominantly in normal and tumor cells of hematopoietic origin, and that its level of expression is much higher in immature cells than in mature cells of each lineage examined (9). *In vitro* induction of terminal differentiation is associated with early disappearance of *myb* transcripts in several myeloid cell lines (9). Thus the c-*myb* gene product may be involved in the control of growth and/or differentiation of hematopoietic cells. AMV causes myeloblastic

or monocytic leukemia in chickens (10), whereas E26 causes erythroblastic as well as myeloblastic or monocytic leukemia in chickens (11). Structural aberrations of the c-myb gene in human, murine, and chicken tumors have also been reported: (i) several murine tumors are associated with insertion of a defective Molony murine leukemia virus into a c-myb gene and with expression of an abnormal c-myb transcript (12-17); (ii) rearrangement of the c-myb was noted in chicken B-cell lymphomas (18) and human melanoma cells (19); (iii) amplification of c-myb has been reported in human myeloid leukemia (20) and colon carcinoma (21). Therefore, c-myb may play a key role in oncogenesis.

Families of nuclear oncogenes (22,23: N.Nomura et al., in preparation), of protein-tyrosine kinases (24) and of thyroid hormone receptor genes (25) have been reported. Each gene family harbors a conserved region that should encode proteins with common function. To obtain an insight into the functions of c-myb in transformation and cell growth, we looked for a gene(s) related to c-myb. Here we report the isolation and characterization of cDNA clones of the human myb-related genes A-myb and B-myb.

### MATERIALS AND METHODS

#### Cells:

Cell lines were derived from a neuroblastoma (NB-1, TGW-III-nu, NB39-nu), Burkitt lymphoma (JBL-1, JBL-3, JBL-5), myeloid cells (KG-1), a T cell lymphoma (Molt-4), a mesothelioma (TC8), an arrhenoblastoma (TC25), a malignant fibrous histiocytoma (NMS10), and carcinomas of the stomach (MKN-1, MKN-28, MKN-45, MKN-74, KATO-III), prostate (PC3, 1013L), thyroid (TC78, TC80), lung (NMS83), colon (CL, Colo320DM), vulva (A431), breast (MCF-7), kidney (253J), and uterus (T24). MKN-1, MKN-28, MKN-45, MKN-74, KATO-III, NB-1, TGW-III-nu and NB39-nu were from T.Suzuki ( Niigata University), JBL-1, JBL-3 and JBL-5 were from I.Miyoshi (Kohchi Medical College), T24, PC3, 1013L and 253J were from Y.Nakagami (Nippon Medical School), TC8, TC25, TC78 and TC80 were from S.Maeda (Nippon Medical School), and KG-1, A431 and Molt4 were

from the Japanese Cancer Research Resources Bank. Colo320DM was purchased from Dainihonsei-yaku, Osaka, Japan.

cDNA library:

The human cDNA libraries used in this work were generously provided by D.P.Dialynas [a  $\lambda$ gt10 cDNA library from mRNAs of the T cell line HPB-MLT (26)], J.E.Sadler [ $\lambda$ gt11, endothelial cells from umbilical vein (27)], P.Chambon [ $\lambda$ gt11, a breast cancer cell line MCF-7 (28)], J.R.de Wet [ $\lambda$ gt11, a hepatoma cell line Li-7 (29)], S.L.C.Woo [ $\lambda$ gt11, liver (30)], W.L.Miller [ $\lambda$ gt10, adrenal (31)], J.M.Puck [ $\lambda$ gt11, peripheral blood lymphocytes (32)], J.L.Millan [ $\lambda$ gt11, testis (33)], C.Betsholtz [ $\lambda$ gt10, a glioma cell line U-343MGa clone 2:6 (34)] and G.J.Roth [ $\lambda$ gt11, an erythroleukemia cell line HEL (35)]. Human placenta and IMR32 ( a neuroblastoma cell line ) cDNA libraries which were constructed in  $\lambda$ gt11 and  $\lambda$ gt10 phage vector respectively, were purchased from Clontech Lab., Inc. (Palo Alto, CA, U.S.A.)

Screening of the cDNA library:

A 2.6kb *EcoRI* fragment of pE2.6 (36), the 1.3kb *HpaII-NcoI* fragment of  $\lambda$ -Amyb1 (this work) and 0.85kb and 1.4kb *EcoRI* fragments of  $\lambda$ -Bmyb1 (this work) were random-primed (37) with [ $\alpha$ - $^{32}$ P]dCTP (3000Ci/mmol) to a specific activity of  $2 \times 10^6$ cpm/ng. Hybridization was performed in solution containing either 30% (relaxed condition) or 50% (stringent condition) formamide, 5xSSC, 0.5%SDS, 5xDenhardt's solution, 100 $\mu$ g/ml of sonicated salmon testis DNA and  $^{32}$ P-labeled probe ( $2 \times 10^6$ cpm/ml) at 37°C for 16 hours. After several washings in 1xSSC, 0.1%SDS at room temperature, filters were finally washed with 0.1xSSC, 0.5%SDS either at 35°C (relaxed condition) or 50°C (stringent condition) for 1 hour.

DNA sequencing:

Sequence analysis was carried out by the dideoxynucleotide chain terminator method with a modification (7-deaza dGTP instead of dGTP) (38,39). Relevant DNA fragments were isolated from  $\lambda$  phage clones by digestion with restriction endonucleases and were cloned into M13mp11, M13mp18 and pUC18 (40). Some sequencing was performed by subcloning appropriate restriction fragments into M13mp11 and M13mp18.

Computer analysis:

Homology studies and other computer analyses were carried out with the University of Wisconsin Computing Group package (41) and IDEAS (42) programs in a VAX/VMS computer (Institute of Medical Science, Tokyo University).


Northern and Southern blot analyses:

Cytoplasmic RNA from cells (43) was passed over oligo (dT)-cellulose. The glyoxylated poly(A)<sup>+</sup> RNA (3µg) was fractionated on 0.7% agarose gel and transferred to a Biotodyne A filter (Pall, New York, U.S.A.) (44). Genomic DNAs were digested with BamHI (Takara Shuzo, Kyoto, Japan), electrophoresed in 0.7% agarose gel, treated, and blotted onto a Biotodyne A filter essentially as described by Southern (45).

RESULTS

Isolation of cDNA clones of myb and myb-related genes

To obtain cDNA clones of the human-myb gene, we screened six kinds of cDNA libraries with a 2.6kb EcoRI fragment of the h-myb genomic clone pE2.6 (36) as a probe. On screening  $3 \times 10^5$  phages of each library, 17 and 7 positive clones, respectively, were isolated from the T cell (HPB-MLT) (26) and the breast cancer cell (MCF-7) cDNA libraries (28). No positive clones were obtained from the other four libraries, namely placenta, liver, umbilical vein and Li-7 cDNA libraries. Several clones from the T cell library were characterized further by physical mapping and partial sequence analysis, and results were consistent with reported findings (46,47). As h-myb, D-myb [the myb gene of Drosophila melanogaster (2,48)], and maize myb (49) have large homologous domains in the N-terminal portion (Fig.4), we thought that this region might be conserved in a gene(s) related to myb. Therefore, we excised the 570bp EcoRI fragment of h-myb from a cDNA clone and used it as a probe [Fig.1 (a)]. Two positive clones were isolated by screening six kinds of cDNA libraries under conditions of reduced stringency. Hybridization with a h-myb probe and partial sequence analysis revealed that these clones had myb-related genes that differed from each other. These newly identified genes related to myb were named A-myb and B-myb, respectively. Both clones were



**Fig.1** cDNA clones of (a) human-myb, (b) human A-myb, and (c) human B-myb

The solid and open boxes represent the coding and non-coding regions, respectively. The hatched box shows a polyA tail. Three conserved domains are indicated by Roman numerals (I, II and III). (a) The 570bp myb probe used for initial screening of myb-related genes is indicated by an underline. (b) Dashed lines indicate a 3' non coding region and a C-terminal portion which have not been cloned yet. Abbreviations: R, EcoRI; B, BamHI; H, HpaII; N, NcoI; K, KpnI; S, StuI. HpaII sites of (a) h-myb and (c) B-myb are not shown.

isolated from the T cell (HPB-MLT) library (26) and were named  $\lambda$ -Amyb1 and  $\lambda$ -Bmyb1, respectively.

#### DNA sequence of the human-A-myb cDNA clone

About 1450bp nucleotide sequence of the insert of the  $\lambda$ -Amyb1 phage was determined (Fig.2). An open reading frame starting with the first ATG codon at position 105 was identified, but the C-terminal region was deleted in this cDNA clone. To obtain other A-myb clones, we screened twelve cDNA libraries with the 1273bp HpaII-NcoI fragment of  $\lambda$ -Amyb1 as a probe under stringent conditions. Six clones were obtained from the MCF-7 cDNA library, and four clones were isolated from the testis cDNA library. In addition, single clones were isolated from the hepatoma cell Li-7, the liver and the peripheral blood cDNA libraries, respectively. Southern hybridization and DNA sequencing analysis showed that a clone isolated from the testis cDNA library, named  $\lambda$ -Amyb2, carried the C-terminal region of A-myb. The 2341bp nucleotide sequence of A-myb cDNA,

Nucleic Acids Research

1 GGAG GGACAGCGC TAGAGATCG GGGAGAAGGA GCATTGCGCG GAGGCTGGAG GAGGCTGACC CGCGTCCCCC CCCAGCCTGC TCCTATGCGG TACTGAGG

105 ATG GCG AAG AGG TCG CGC AGT GAG GAT GAG GAT GAC CTT CAG TAT GCC GAT CAT GAT TAT GAA GTA CCA CAA AAA GBA CTG AAG  
Met Ala Lys Arg Ser Arg Ser Glu Asp Glu Asp Asp Asp Leu Gln Tyr Ala Asp His Asp 20  
1 10 20 30

195 AAA CTC TGG AAC AGA GTA AAA TGG ACA AGG GAC GAG GAT GAT AAA TTA AAG AAG TTG GTT GAA CAA CAT GGA ACT GAT GAT TGG ACT CTA  
Lys Leu Trp Asn Arg Val Lys Trp Thr Arg Asp Glu Asp Lys Lys Leu Val Glu Gln His Gly Thr Asp Asp Trp Thr 60  
40 50 60

285 ATT GCT AGT CAT CTT CAA AAT CGC TCT GAT TTT CAG TGC CAG CAT CGA TGG CAG AAA GTT TTA AAT CCT GAA TTG ATA AAG GGT CCT TGG  
Ile Ala Ser His Leu Gln Asn Arg Ser Asp Phe Gln Cys Gln His Arg Trp Gln Lys Val Leu Asn Pro Glu Leu Ile Lys Gly Pro Trp 90  
70 80 90

375 ACT AAA GAA GAA GAT CAG AGG GTT ATT GAA TTA GTT CAG AAA TAT GGG CCA AAA AGA TGG TCT TTA ATT GCA AAA CAT TTA AAA GGA AGA  
Thr Lys Glu Glu Asp Gln Arg Val Ile Glu Leu Val Gln Lys Tyr Gly Pro Lys Arg Trp Ser Leu Ile Ala Lys His Leu Lys Gly Arg 120  
100 110 120

465 ATA GGC AAG CAG TGT GAA GAA AGA TGG CAT AAT CAT CTG AAT CCT GAG GTA AAG AAA TCT TCC TGG ACA GAA GAG GAC AGG ATC ATC  
Ile Gly Lys Gln Cys Arg Glu Arg Trp His Asn His Leu Asn Pro Glu Val Lys Lys Ser Ser Trp Thr Glu Glu Glu Asp Arg Ile Ile 150  
130 140 150

555 TAT GAA GCA CAT AAG CGC TTG GGA AAT CBT TGG GCA GAA ATT GCC AAA CTA CTT CCA GGA AGG ACT GAT AAT TCT ATC AAA AAT CAT TGG  
Tyr Glu Ala His Lys Arg Leu Gly Asn Arg Trp Ala Glu Ile Ala Lys Leu Leu Pro Gly Arg Thr Asp Asn Ser Ile Lys Asn His Trp 180  
160 170 180

645 AAT TCT ACT ATG CGA AGA AAA GTG GAA CAG GAG GGC TAT TTA CAA GAT GGA ATA AAA TCA GAA CGA TCT TCA TCT AAA CTT CAA CAC AAA  
Asn Ser Thr Met Arg Arg Lys Val Glu Gln His Gln Gly Tyr Leu Gln Asp Gly Ile Lys Ser Ser Glu Arg Ser Ser Ser Lys Leu Gln His 210  
190 200 210

735 CCT TGT GCA GCT ATG CAT GAT ATG CAA ACC CAG AAT CAG TTT TAC ATA CTT GGT CAG ATC CCT CGG TAT CAG TAT GTG TCA CCT GAA GGC  
Pro Cys Ala Ala Met Asp His Met Gln Thr Gln Asn Gln Phe Tyr Ile Pro Val Gln Ile Pro Gly Tyr Gln Tyr Val Ser Pro Glu Gly 240  
220 230 240

825 AAT TGT ATA GAA CAT GTT CAG CCT ACT TCT GCC TTT ATT CAG CAA CCC TTC ATT GAT GAA GAT CCT GAT AAG GAA AAG AAA ATA AAG GAA  
Asn Cys Ile Glu His Val Gln Pro Thr Ser Ala Phe Ile Gln Gln Pro Phe Ile Asp Glu Asp Pro Asp Lys Glu Lys Lys Ile Lys Glu 270  
250 260 270

915 CTT GAG ATG CTT CTT ATG TCA GCT GAG AAT GAA GTT AGA AGA AAG CGA ATT CCA TCA CAG CCT GGA AGT TTT TCT AGC TGG TCT GGT AGT  
Leu Glu Met Leu Leu Met Ser Ala Glu Asn Glu Val Arg Arg Lys Arg Ile Pro Ser Gln Pro Gly Ser Phe Ser Ser Trp Ser Gly Ser 300  
280 290 300

1005 TTC CTC ATG GAT GAT AAC ATG TCT AAT ACT CTA AAT AGC CTT GAC GAG CAC ACT AGT GAG TTT TAC AGT ATG GAT GAA AAT CAG CCT GTG  
Phe Leu Met Asp Asp Asn Met Ser Asn Thr Leu Asn Ser Leu Asp Glu His Thr Ser Glu Phe Tyr Ser Met Asp Glu Asn Glu Val 330  
310 320 330

1095 TCT GCT CAG CAG AAT TCA CCC ACA AAG TTC CTG GCC GTG GAG GCA AAC GCT GTG TTA TCT TCC TTT CAG ACC ATC CCA GAA TTT GCA GAG  
Ser Ala Gln Gln Asn Ser Pro Thr Lys Phe Leu Ala Val Glu Ala Asn Ala Val Leu Ser Ser Ser Leu Gln Thr Ile Pro Glu Phe Ala Glu 360  
340 350 360

1185 ACT CTA GAA CTT ATT GAA TCT GAT CCT GTA GCA TGG AGT GAC GTT ACC AGT TTT GAT ATT TCT GAT GCT GCT GCT CCT ATC AAA TCC  
Thr Leu Glu Leu Ile Glu Ser Asp Pro Val Ala Trp Ser Asp Val Thr Ser Phe Asp Ile Ser Asp Ala Ala Ala Ser Pro Ile Lys Ser 390  
370 380 390

1275 ACC CCA GTT AAA TTA ATG AGA ATT CAG CAC AAT GAA GGA GCC ATG GAA TGC CAA TTT AAC GTC AGT CTT GTA CTT GAA GGG AAA AAA AAC  
Thr Pro Val Lys Met Arg Ile Glu His Asn Glu Gly Ala Met Glu Cys Gln Phe Asn Val Ser Leu Val Leu Glu Gly Lys Lys Asn 420  
400 410 420

1365 ACT TGT AAT GGT GGC AAC AGT GAA GCT GTT CCT TTA ACA TCC CCA AAT ATA GCC AAG TTT AGC ACT CCA CCA GCC ATC CTA AGA AAG AAG  
Thr Cys Asn Gly Gly Asn Arg Val Gly His Ser Pro Glu Ser Ser Glu Leu Arg Asp Gly Ser Leu Asn Asp Gly Gly Asn Met Ala Leu Lys His Thr 450  
430 440 450

1455 AGA AAA ATG CGA GTG GGT CAT TCC CCA GGC AGC GAA CTT AGG GAT GGC TCA TTG AAC GAT GGT GGT AAT ATG CGC GTA AAA CAT ACA CCA  
Arg Lys Met Arg Val Gly His Ser Pro Glu Ser Ser Glu Leu Arg Asp Gly Ser Leu Asn Asp Gly Gly Asn Met Ala Leu Lys His Thr 480  
460 470 480

1545 CTG AAA ACA CTA CCA TTT TCT CCT TCA CAG TTT TTC AAC ACA TGT CCT GGT AAT GAA CAA CTT AAT ATA GAA AAT CCT TCA TTT ACA TCA  
Leu Lys Thr Leu Pro Phe Ser Pro Ser Gln Phe Phe Asn Thr Cys Pro Gly Asn Glu Gln Leu Asn Ile Glu Asn Pro Ser Phe Thr 510  
490 500 510

1635 ACC CCT ATT TGT GGG CAG AAA GCT CTC ATT ACA ACT CCT CTT CAT AAG GAA ACA ACT CCC AAA GAT CAA AAG GAA AAT GTA GGG TTT AGA  
Thr Pro Ile Cys Gly Gln Lys Ala Leu Ile Thr Thr Pro Leu His Lys Glu Thr Thr Pro Lys Asp Gln Lys Glu Asn Val Gly Phe Arg 540  
520 530 540

1725 ACA CCT ACT ATT AGA AGA TCT ATA CTG GGT ACC ACA CGA AGA ACT CCT ACT CTT TTT AAG AAT GCG CTT GCT GCT CAG GAG AAA AAT  
Thr Pro Thr Thr Ile Arg Arg Ser Ile Leu Gly Thr Thr Pro Arg Thr Pro Thr Pro Phe Lys Asn Ala Leu Ala Ala Gln Glu Lys Lys Tyr 570  
550 560 570

1815 GGA CCT CTT AAA ATT GTG TCC CAG CCA CTT GCT TTC TTG GAA GAA GAT ATT CGG GAA GAT TTA AAA GAA GAA ACT GGA ACA GAC CTA TTC  
Gly Pro Leu Lys Ile Val Ser Gln Pro Leu Ala Phe Leu Glu Glu Asp Ile Arg Val Leu Lys Glu Glu Thr Gly Thr Asp Leu Phe 600  
580 590 600

1905 CTC AAA GAG GAA GAT GAA CCT GCT TAC AAA AGC TGC AAA CAA GAG AAT ACC GCT TCT GGG AAG AAA GTC AGA AAA TCA CTA GTC TTA GAT  
Lys Lys Glu Glu Asp Glu Pro Ala Tyr Lys Ser Cys Lys Gln Glu Asn Thr Ala Ser Gly Lys Lys Val Arg Lys Ser Leu Val Leu Asp 630  
610 620 630

1995 AAT TGG GAA AAA GAA GAA TCA GGC ACT CAA CTG TTG ACT GAA GAC ATT TCA GAC ATG CAG TCA GAA AAT AGA TTT ACT ACA TCC TTA TTA  
Asn Trp Glu Ser Lys Glu Glu Ser Gly Thr Gln Leu Leu Thr Glu Asp Ile Ser Asp Met Gln Ser Glu Asn Arg Phe Thr Thr Ser Leu 660  
640 650 660

2085 ATG ATA CCA TTA TTG GAA ATA CAT GAC AAT AGG TGC AAT TTG ATT CCT GAA AAA CAA GAT ATA AAT TCA ACC AAC AAA ACA TAT ACA CTT  
Met Ile Pro Leu Leu Glu Ile His Asp Asn Arg Cys Asn Leu Ile Pro Glu Lys Gln Asp Ile Asn Ser Thr Asn Lys Thr Tyr Thr 690  
670 680 690

2175 ACT AAA AAG AAA CCA AAC CCT AAC ACT TCC AAA GTT GTC AAA TTG GAA AAG AAT CTT CAG TCA AAT TGT GAA TGG GAA ACA GTG GTT TAT  
Thr Lys Lys Lys Pro Asn Pro Asn Thr Ser Lys Val Val Lys Leu Glu Lys Asn Leu Gln Ser Asn Cys Glu Trp Glu Thr Val Val Tyr 720  
700 710 720

2265 GGG AAG ACA GAA GAC CAA CTT ATT ATG ACT GAA CAA GCA AGA AGA TAT CTG AGT ACT TAC ACA GCT ACC AGT AGT AC 2341  
Gly Lys Thr Glu Asp Gln Leu Ile Met Thr Glu Gln Ala Arg Arg Tyr Leu Ser Thr Tyr Thr Ala Thr Ser Ser 740  
730 740

which encodes 745 amino acid residues, was shown in Fig.2. Although no termination codon was observed, we speculate that the open reading frame of A-myb might end within 20 additional codons ( see DISCUSSION ).

#### DNA sequence of the human-B-myb cDNA clones

To obtain other B-myb clones, we screened eight cDNA libraries further with the 0.85kb and 1.4kb EcoRI fragments of  $\lambda$ -Bmyb1 as probes under stringent conditions. Another ten clones were obtained from the T cell cDNA library, and 19 clones were isolated from the peripheral blood lymphocyte cDNA library. In addition, two clones were obtained from the liver cDNA library, four from the umbilical vein library and one each from the placenta and Li-7 cell cDNA libraries. The sequence of human-B-myb was determined from the DNA sequences of several representative clones (Fig.3). An open reading frame of 2100bp starting with the first ATG codon at position 128 was identified. The flanking nucleotides do not match the consensus sequence of Kozak (50), but an in-frame termination codon was found 70bp upstream of this ATG codon. The predicted open reading frame could encode a protein of 700 amino acid residues, with a calculated molecular weight of 78,791. Two polyadenylation sites were found, although these were two base pairs, apart. The insert of one clone ended at position 2627, followed by a polyA tail. The inserts of the other two clones ended at position 2625.

#### Homology among h-myb, A-myb, B-myb and D-myb

Fig.4 shows the alignment of homologous domains of the h-myb, A-myb, B-myb and D-myb proteins. Domain I, which is 161 amino acid long, is well conserved in the myb gene family. For example, the homology of this domain in h-myb and A-myb is 90% at the amino acid level. Moreover 8 of 17 amino acid changes

#### Fig.2 Human A-myb cDNA nucleotide sequence and the deduced amino acid sequence

Although the C-terminal end is not known, the sequence of 745 amino acids is shown. Three conserved domains (I,II and III) are underlined. The in-frame stop codon, which is 4 bp upstream of the putative initiation codon, is boxed. The insert of the  $\lambda$ -Amyb1 phage was terminated and polyadenylated at nucleotide position 1448.

Nucleic Acids Research

GCTGACG CCTTCAGCG

1  
 18 CBGCCCCGGG CCGGAGCG CCGAGCAG CCGGTCCTG CCCGGCC GGTCCCGCT CCGGCTCTG CCGCGGGG GCGAGCAG GCGCGTCCG GCGCGGGG

128 ATG TCT CGG CGG ACG CGC TGC GAG GAT CTG GAT GAG CTG CAC TAC CAG CAG ACA GAT TCA GAT GCG CAG GAG CAG ACG AAG TGC  
 Met Ser Arg Arg Thr Arg Cys Glu Asp Leu Asp Glu Leu His Tyr Gln Asp Thr Asp Ser Asp Val Pro Glu Gln Arg Asp Ser Lys Cys  
 1 10 20 30

218 AAG GTC AAA TGG ACC CAT GAG GAG GAG GAG CAG CTG AGG GCC CTG GTG AGG CAG TTT GGA CAG CAG CAG TGG AAG TTC CTG GCC ACG CAC  
 Lys Val Lys Trp Thr His Glu Glu Asp Glu Leu Arg Ala Leu Val Arg Gln Phe Gly Gln Gln Asp Trp Lys Phe Leu Ala Ser His  
 40 50 60

308 TTC CCT AAC CGC ACT GAC CAG CAA TGC CAG TAC AGG TGG CTG AGA GTT TTG AAT CCA GAC CTT GTC AAG GGG CCA TGG ACC AAA GAG GAA  
 Phe Pro Asn Arg Thr Asp Gln Gln Cys Gln Tyr Arg Trp Leu Arg Val Leu Asn Pro Asp Leu Val Lys Gly Pro Trp Thr Lys Glu Gly  
 70 80 90

398 GAC CAA AAA GTC ATC GAG CTG GTT AAG AAG TAT GGC ACA AAG CAG TGG ACA CTG ATT GCC AAG CAG CTG AAG GGC CGG CTG GGG AAG CAG  
 Asp Gln Lys Val Ile Glu Leu Val Lys Lys Tyr Gly Thr Lys Gln Trp Thr Leu Ile Ala Lys His Leu Lys Gly Arg Leu Gly Lys Gln  
 100 110 120

488 TGC CGT GAA CGC TGG CAC AAC CAC CTC AAC CCT GAG GTG AAG AAG TCT TGC TGG ACC GAG GAG GAG CAG CAG ATC ATC TGC GAG GCC CAC  
 Cys Arg Glu Arg Trp His Asn His Leu Asn Pro Glu Val Lys Lys Ser Cys Trp Thr Gly Gln Glu Asp Arg Ile Ile Cys Glu Ala His  
 130 140 150

578 AAG GTG CTG GGC AAC CGC TGG GCC GAG ATC ACC GGC AAG ATG TTG CCA GGG AGC ACA GAC AAT GCT GTG AAG AAT CAC TGG AAC TCT ACC ATC  
 Lys Val Leu Gly Asn Arg Trp Ala Glu Ile Ala Lys Met Leu Pro Gly Arg Thr Asp Asn Ala Val Lys Asn His Trp Asn Ser Thr Ile  
 160 170 180

668 AAA AGG AAG GTG GAC ACA GGA GGC TTC TTG AGC GAG TCC AAA GAC TGC AAC CCC CCA GTG TAC TTG CTG CTG GAG CTC GAG CAG AAG GAC  
 Lys Arg Glu Arg Trp His Val Asp Thr Gly Gly Phe Leu Ser Lys Asp Cys Lys Pro Val Tyr Leu Ser Arg Ser Ser Arg Gly Glu Leu Asp  
 190 200 210

758 GGC CTC CAG AGT GCC CAG CCC ACG GAA GGC CAG GGA AGT CTT CTG ACC AAG TGG CCC TCC GTC CCT CCT ACC ATA AAG GAG GAG GAA AAG  
 Gly Leu Gln Ser Ala Gln Pro Thr Glu Gly Gln Gly Ser Leu Leu Thr Asn Trp Pro Ser Val Pro Pro Thr Ile Lys Cys Glu Glu Leu  
 220 230 240

848 AGT GAG GAG GAA CTT GCA GCA GCC ACC ACA TCG AAG GAA CAG GAG CCC ATC GGT ACA GAT CTG CAG GCA GTG CGA ACA CCA GAG CCC TTG  
 Ser Glu Glu Glu Leu Ala Ala Ala Thr Thr Ser Lys Glu Gln Glu Pro Ile Gly Thr Asp Leu Asp Ala Val Arg Thr Pro Glu Pro Leu  
 250 260 270

938 GAG GAA TTT CCG AAG CGT GAG CAG CAG GAA GGC TCC CCA CCA GAA ACG AGC CTC CCT TAC AAG TGG GTG GTG GAG GCA GCT AAC CTC CTC  
 Glu Gly Phe Pro Lys Arg Asp Thr Gly Gly Phe Leu Ser Lys Asp Glu Ser Pro Pro Glu Thr Ser Leu Ala Pro Tyr Lys Trp Val Val Glu Ala Asn Leu  
 280 290 300

1028 ATC CCC GCT GTG GGT TCT AGC CTC TCT GAA GCC CTG GAG TTG ATC GAG TGG GAC CCT GAT GCT TGG TGT GAC CTG AGT AAA TTT GAC CTC  
 Ile Pro Ala Val Gly Ser Ser Leu Ser Glu Ala Leu Asp Leu Ile Glu Ser Asp Pro Asp Ala Trp Cys Asp Leu Ser Lys Phe Asp Leu  
 310 320 330

1118 CCT GAG GAA CCA TCT GCA GAG CAG AGT ATC AAC AAC AGC CTA GTG CAG CTG CAA GGG TCA CAT CAG CAG CAA GTC CTG CCA CCC CGG CAG  
 Pro Glu Glu Pro Ser Ala Glu Asp Ser Ile Asn Asn Ser Leu Val Gln Leu Gln Ala Ser His Gln Gln Gln Val Leu Pro Pro Arg Gln  
 340 350 360

1208 CCT TCC GCC CTG GTG CCC AGT GTG ACC GAG TAC CGC GAT GGC CAC ACC ATC TCA GAC CTG ACG CGG AGC AGC CGG GGC GAG CTG ATC  
 Pro Ser Ala Leu Val Thr Pro Ser Val Thr Glu Tyr Arg Leu Asp Gly His Thr Ile Ser Asp Leu Ser Arg Ser Ser Arg Gly Glu Leu Ile  
 370 380 390

1298 CCC ATC TCC CCC AGC ACT GAA GTC GGG GGC TCT GGC ATT GGC ACA CGG CCC TCT GTG CTC AAG CGG CAG AGG AAG AGG CGT GTG GCT CTG  
 Pro Ile Ser Pro Ser Thr Thr Glu Val Gly Gly Ser Gly Ile Gly Thr Pro Pro Ser Val Leu Lys Arg Gln Arg Lys Arg Arg Val Ala Leu  
 400 410 420

1388 TCC CCT GCT ACT GAG AAT AGC ACC AGT CTG TCC TTC CTG GAT TCC TGT AAC AGC CTC ACG CCC AAG AGC ACA CCT GTT AAG ACC CTG CCC  
 Pro Pro Val Thr Glu Asn Ser Thr Ser Leu Ser Phe Leu Asp Ser Cys Asn Ser Leu Thr Pro Leu Lys Thr Leu Phe Leu Thr Leu  
 430 440 450

1478 TTC TCG CCC TCC CAG TTT CTG AAC TTC TGG AAC AAA CAG CAG ACA TTG CAG CTG GAG ACG CCC TCG CTG ACA TCC ACC CCA GTG TGC AGC  
 Phe Ser Pro Ser Ser Gln Phe Leu Asn Phe Trp Asn Lys Gln Asp Thr Leu Glu Leu Glu Ser Pro Ser Leu Thr Ser Thr Pro Val Cys Ser  
 460 470 480

1568 CAG AAG GTG GTG GTC ACC ACA CCA CTG CAC CGG GAC AAG ACA CCC CTG CAC CAG AAA CAT GCT GCG TTT GTA ACC CCA GAT CAG AAG TAC  
 Gln Lys Val Val Val Thr Thr Pro Leu His Arg Asp Lys Thr Pro Leu His Gln Lys His Ala Ala Phe Val Thr Pro Asp Gln Lys Tyr  
 490 500 510

1658 TCC ATG GAC AAC ACT CCC CAC ACG CCA ACC CCG TTC AAG AAC GCC CTG GAG AAG TAC GGA CCC CTG AAG CCC CTG CCA CAG ACC CGG CAC  
 Ser Met Asp Asn Thr Pro His Thr Pro Thr Phe Lys Asn Ala Leu Glu Lys Tyr Arg Pro Leu Lys Pro Leu Pro Gln Thr Pro His  
 520 530 540

1748 CTG GAG GAG GAC TTG AAG GAG GTG CTG CGT TCT GAG GCT GGC ATC GAA CTC ATC ATC GAG GAC GAC ATC AGG CCC GAG AAG CAG AAG AGG  
 Leu Glu Glu Asp Leu Lys Glu Val Leu Arg Ser Glu Ala Gly Ile Glu Leu Ile Ile Glu Asp Asp Ile Arg Pro Glu Lys Gln Lys Arg  
 550 560 570

1838 AAG CCT GGG CTG CCG CGG AGC CCC ATC AAG AAA GTC CGG AAG TCT CTG GCT CTT GAC ATT GTG GAT GAG GAT GTG AAG CTG ATG ATG TCC  
 Lys Pro Gly Leu Arg Arg Ser Pro Ile Lys Lys Val Arg Lys Ser Leu Ala Leu Asp Ile Val Asp Glu Asp Val Lys Leu Met Met Ser  
 580 590 600

1928 ACA CTG CCC AAG TCT CTA TCC TTG CCG ACA ACT GCC TCT CTA AAC TCT TCC AGC CTC ACC CTG CTA GGT ATE AAA GAA GAC AAC AGC TTG  
 Thr Leu Pro Lys Ser Leu Ser Leu Pro Thr Thr Ala Pro Ser Asn Ser Ser Ser Leu Thr Leu Ser Gly Ile Lys Glu Asp Asn Ser Leu  
 610 620 630

2018 CTC AAC CAG GGC TTC TTG CAG GCC AAG CCC GAG AAG GCA GCA GTG GCC CAG AAG CCC CGA AGC CAC TTC ACG ACA CCT GCC CCT ATG TCC  
 Leu Asn Gln Gly Phe Leu Gln Ala Lys Pro Glu Lys Ala Ala Val Ala Gln Lys Pro Arg Ser His Phe Thr Thr Pro Ala Pro Met Ser  
 640 650 660

2108 AGT GCC TGG AAG ACG GTG GCC TGC GGG GGG ACC AAG CAG CAG CTT TTC ATG CAG AAG AAA GCC CGG CAG CTC CTG GGC CGC GTG AAG CCC  
 Ser Ala Trp Lys Thr Val Ala Cys Gly Gly Thr Arg Asp Gln Leu Phe Met Gln Glu Lys Ala Arg Gln Leu Leu Gly Arg Leu Lys Pro  
 670 680 690

2198 AGC CAC ACA TCT CGG ACC CTC ATC TTG TCG TGA GGTGTTGAG GGTGTACGA GCCATTCTC ATGTTTACG GGGTTGTGGG GGCAGAGGGG GTCTGTGAAT  
 Ser His Thr Ser Arg Thr Leu Ile Leu Ser End  
 700

2300 CTGAGATCA TTCAGTGAC CTCTCGAAG GAGCCTCTG CCACCAGCCC CTCCCAGAC TCTCAGGTGG AGGCACAGCC GCCATGTGCT GCCCTGTTCG CBAGCCAGC

2410 TGTGGCGCGC TCTGDTGCT AACACAAGG TTCCACTTCC AGGTCTGCCCT GGTTCCTCC CCAAGGCCAC AGGGAGCTCC CTGACCTCT CCGAGCCCA GTCAGGGCT

2520 GGCCCTCATCT CAGACCTCGC TTAGATGGG GGATGTGGCC AGGGGTGCTC CTGTGCTAC CCTCTCTGG TGCATTTTTT TGSAACTATA AATTTGCCCT TCTCTTTGAA

2630 AAAAAAAA



are conservative ones. Domain II, which is about 85 amino acid long, is less well conserved. Domain III is seen in the C-terminal region as a short stretch. Domains I and II are located in the region that is well conserved in human, mouse and chicken c-myb.

#### mRNAs of A-myb and B-myb

poly(A)<sup>+</sup> RNAs were prepared from various cell lines and subjected to Northern blotting as described by Thomas (44). After hybridization with the A-myb probe under stringent conditions, a band of 5.0kb was detected [Fig.5 (a)]. Hematopoietic cell lines, including Burkitt lymphoma (JBL-1, -3, -5) and T cell lymphoma (Molt-4) expressed A-myb mRNA at high levels. Carcinoma cell lines from the kidney (253J), uterus (T24) and colon (Colo320DM) and a sarcoma cell line (NMS10) also expressed the A-myb message at high levels, but the other cell lines gave either a weak or no visible band of A-myb mRNA. As the transcript of A-myb is 5.0kb, the A-myb cDNA sequence determined, which is 2341bp in length, should have a deletion of a large portion of either 5' or 3' non translated region. On hybridization with the 0.85kb and 1.4kb EcoRI fragments of  $\lambda$ -Bmyb1, B-myb mRNA of 2.6kb was detected [Fig.5 (b)]. Augmented expression of B-myb was observed in JBL-1, -3, -5, Molt-4, Colo320DM, A431, NB39-nu, KG-1 and MKN-1, but B-myb mRNAs were detected in all the cells examined. As the B-myb mRNA is 2.6kb, the B-myb cDNA sequence determined, which is 2638bp in length, should represent the entire B-myb mRNA. Enhanced c-myb expression was detected in JBL-1, -3, -5, KG-1 and Molt-4 [Fig.5 (c)]. Messages of c-myb were weakly expressed in Colo320DM, CL, TGW-III-nu, A431, NB39-nu, MKN-74, KATO III, PC3 and 1013L. Although strong c-myb expression was detected in hematopoietic cells, the A-myb and B-myb gene seem to be more broadly expressed than c-myb.

#### Fig.3 Nucleotide sequence of human B-myb cDNA and deduced amino acid sequence

Three conserved domains (I,II and III) are underlined. The putative polyadenylation signal (AATAAA) is boxed. The in-frame stop codon, which is 70bp upstream of the putative initiation codon, is also boxed.







Fig.5 mRNAs of (a) A-myb, (b) B-myb and (c) c-myb poly(A)<sup>+</sup> RNA was analyzed as described in Materials and Methods. The fragment used as A-myb probe is the 1.2kb HpaII-NcoI fragment of  $\lambda$ -Amyb1 ( nucleotides 43-1317 in Fig.2 ). The B-myb probe used is the insert of  $\lambda$ -Bmyb1 ( nucleotides 98-2366 in Fig.3 ). The fragments which include entire coding sequences of c-myb were used as a probe of c-myb. Lanes: 1,T24; 2,CL; 3,MKN-1; 4, MKN-28; 5,MKN-45; 6,MKN-74; 7,KATO-III; 8,PC3; 9,1013L; 10,253J; 11,NMS10; 12,JBL-1; 13,JBL-3; 14,JBL-5; 15,NMS83; 16,TC78; 17, NB-1; 18,TC25; 19,TC8; 20,TC80; 21,Colo320DM; 22,TGW-III-nu; 23,A431; 24,NB39-nu; 25,KG-1; 26,Molt-4; 27,MCF-7.

may be responsible for common functions of the myb gene family, such as binding to a specific region(s) of DNA (8) and/or interaction with a specific protein(s), as in the case of fos (51). The v-myb genes of AMV and E26 virus do not have part of the first stretch of three tandem repeats. Therefore, two of the three repeated sequences may be enough for the function of domain I. As the C-terminal region including domains II and III is deleted in the v-myb gene, these domains may play a regulatory role in the function of the myb gene family. Retroviral integration in leukemia cell lines WEHI-265,



**Fig.6** Evolutionary conservation of the A-myb (lanes 1-4) and B-myb (lanes 5-8) genes

DNAs (10 $\mu$ g each) from human placenta (lanes 1 and 5), mouse NIH3T3 cells (lanes 2 and 6), Fisher rat (lanes 3 and 7) and chicken red blood cells (lanes 4 and 8) were digested with BamHI and analyzed by Southern blot hybridization. The fragments used as probes are the same as Fig.5. A HindIII digest of  $\lambda$  DNA was used as size markers.

WEHI-274 and NSF-60 was observed at the positions corresponding to amino acid residues 48, 72 and 396, respectively, within the mouse c-myb gene (12,14,15,16,17). Therefore, either truncation of the N-terminal region or deletion of the C-terminal region including domains II and III might activate or deregulate the myb gene, playing a key role in neoplastic transformation. The numbers of codons downstream of domain III of h-myb, B-myb and D-myb are 14, 19 and 32, respectively, whereas 12 codons were observed beyond the boundary of A-myb domain III (Fig.2). Therefore we speculate that the missing codons of the A-myb C-terminal end might be no more than 20 codons. In preliminary studies, A-myb was mapped in chromosome 8 of the human genome (M.Yoshida and N.Nomura, unpublished).

The mRNA expression pattern of the myb gene family in 27 cell lines was examined. Lymphoid cell lines, including Burkitt lymphoma (JBL-1, -3, -5) and T cell lymphoma (Molt-4) express high levels of A-myb, B-myb and c-myb mRNAs. This suggests that concomitant expression of the myb gene family might be relevant to genesis and/or progression of T cell and B cell lymphoma. Analyses of possible changes in A-myb and B-myb expression

associated with changes in differentiation states of hematopoietic cells are in progress.

#### ACKNOWLEDGMENTS

We thank T.Kunieda for DNAs of mouse NIH3T3 cells and Fisher rats, M.Ide for excellent technical assistance and T.Yamamoto and H.Mitsui for helpful discussions. We also thank D.P.Dialynas, P.Chambon, J.E.Sadler, D.R.Helinski, S.L.C.Woo, T.Chandra, W.L.Miller, J.M.Puck, J.L.Millan, C.Betsholtz and G.J.Roth for providing cDNA libraries. We are grateful to N.Miyajima, A.Ito, M.Yamamoto for help in computer analysis, and T.Suzuki, I.Miyoshi, Y.Nakagami and S.Maeda and the Japanese Cancer Research Resources Bank for cell lines. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.

\*To whom correspondence should be addressed

#### REFERENCES

1. Bergmann, D.G., Souza, L.M., and Baluda, M.A. (1981) *J.Virology* 40, 450-455.
2. Peters, C.W.B., Sippel, A.E., Vingron, M. and Klempnauer, K.-H. (1987) *EMBO J* 6, 3085-3090.
3. Roussel, M., Saule, S., Lagrou, C., Rommens, C., Beug, H., Graf, T. and Stehelin, D. (1979) *Nature (London)* 281, 452-455.
4. Souza, L.M., Strommer, J.N., Hillyard, R.L., Komaromy, M.C. and Baluda, M.A. (1980) *Proc.Natl.Acad.Sci. USA* 77, 5177-5181.
5. Boyle, W.S., Lampert, M.A., Lipsick, J.S. and Baluda, M.A. (1984) *Proc.Natl.Acad.Sci. USA* 81, 4265-4269.
6. Klempnauer, K.-H., Ramsay, G., Bishop, J.M., Moscovici, M.G., Moscovici, C., McGrath, J.P. and Levinson, A.D. (1983) *Cell* 33, 345-355.
7. Klempnauer, K.-H., Symonds, G., Evan, G.I. and Bishop, J.M. (1984) *Cell* 37, 537-547.
8. Biedenkapp, H., Borgmeyer, U., Sippel, A.E. and Klempnauer, K.-H. (1988) *Nature (London)* 335, 835-837.
9. Westin, E.H., Gallo, R.C., Arya, S.K., Eva, A., Souza, L.M., Baluda, M.A., Aaronson, S.A. and Wong-Staal, F. (1982) *Proc. Natl.Acad.Sci. USA* 79, 2194-2198.
10. Moscovici, C. (1975) *Curr. Top. Microbiol. Immunol.* 171, 79-101.
11. Radke, K., Beug, H., Kornfield, S., and Graf, T. (1982) *Cell* 31, 643-653.
12. Gonda, T.J., Cory, S., Sobieszczuk, P., Holtzman, D., and Adams, J.M. (1987) *J.Virology* 61, 2754-2763.
13. Mushinski, J.F., Potter, M., Bauer, S.R. and Reddy, E.P. (1983) *Science* 220, 795-798.
14. Rosson, D., Dugan, D. and Reddy, E.P. (1987) *Proc.Natl.Acad. Sci. USA* 84, 3171-3175.

15. Shen-Ong, G.L.C., Morse III, H.C., Potter, M. and Mushinski, S. (1986) *Mol.Cell.Biol.* 6, 380-392.
16. Weinstein, Y., Cleveland, J.L., Askew, D.S., Rapp, U.R. and Ihle, J.N. (1987) *J.Virology* 61, 2339-2343.
17. Weinstein, Y., Ihle, J.N., Lavu, S. and Reddy, E.P. (1986) *Proc.Natl.Acad.Sci. USA* 83, 5010-5014.
18. Kanter, M.R., Smith, R.E., and Hayward, W.S., (1988) *J.Virology* 62, 1423-1432.
19. Linnenbach, A.J., Huebner, K., Reddy, E.P., Herlyn, M. Parmiter, A.H., Nowell, P.C. and Koprowski, H. (1988) *Proc. Natl.Acad.Sci. USA* 85, 74-78.
20. Pelicci, P.G., Lanfrancone, L., Brathwaite, M.D., Wolman, S.R., and Dalla-Favera, R. (1984) *Science* 224, 1117-1121.
21. Alitalo, K., Winqvist, R., Lin, C.C., De La Chapelle, A., Schwab, M., and Bishop, J.M. (1984) *Proc.Natl.Acad.Sci. USA* 81, 4534-4538.
22. Ryder, K., Lau, L.F. and Nathans, D. (1988) *Proc.Natl.Acad. Sci. USA* 85, 1487-1491.
23. Kaye, F., Battey, J., Nau, M., Brooks, B., Seifter, E., De Greve, J., Birrer, M., Sausville, E. and Minna. J. (1988) *Mol.Cell.Biol.* 8, 186-195.
24. Hunter, T. (1987) *Cell* 50, 823-829.
25. Giguere, V., Yang, N., Segui, P. and Evans, R.M. (1988) *Nature (London)* 331, 91-94.
26. Dialynas, D.P., Murre, C., Quertermous, T., Boss, J.M., Leiden, J.M., Seidman, J.G. and Strominger, J.L. (1986) *Proc. Natl.Acad.Sci.USA.* 83, 2619-2623.
27. Sadler, J.E., Shelton-Inloes, B.B., Sorace, J.M., Harlan, J.M., Titani, K. and Davie, E.W. (1985) *Proc. Natl. Acad. Sci. USA.* 82, 6394-6398.
28. Walter, P, Green, S., Greene, G., Krust, A., Bornert, J.-M. Jeltsch, J.-M., Staub, A., Jensen, E., Scrace, G., Waterfield, M. and Chambon, P. (1985) *Proc.Natl.Acad.Sci. USA.* 82, 7889-7893.
29. de Wet, J.R., Fukushima, H., Dewji, N.N., Wilcox, E., O'Brien, J.S. and Helinski, D.R. (1984) *DNA* 3, 437-447.
30. Kwok, S.C.M., Ledley, F.D., DiLella, A.G., Robson, K.J.H. and Woo, S.L.C. (1985) *Biochemistry* 24, 556-561.
31. Chung, B.-C., Matteson, K.J., Voutilainen, R., Mohandas, T.K. and Miller, W.L. (1986) *Proc.Natl.Acad. Sci.USA.* 83, 8962-8966.
32. Gold, D.P., Puck, J.M., Pettey, C.L., Cho, M., Coligan, J., Woody, J.N. and Terhorst, C. (1986) *Nature (London)* 321, 431-434.
33. Millan, J.L., Driscoll, C.E., LeVan, K., M. and Goldberg, E. (1987) *Proc.Natl.Acad.Sci.USA.* 84, 5311-5315.
34. Betsholtz, C., Johnsson, A., Heldin, C.-H., Westermark, B., Lind, P., Urdea, M.S., Eddy, R., Shows, T.B., Philpott, K., Mellor, A.L., Knott, T.J. and Scott, J. (1986) *Nature (London)* 320, 695-699.
35. Lopez, T.A., Chung, D.W., Fujikawa, K., Hagen, F.S., Papayannopoulou, T. and Roth, G.J. (1987) *Proc.Natl.Acad. Sci.USA* 84, 5615-5619.
36. Franchini, G., Wong-Staal, F., Baluda, M.A., Lengel, C. and Tronick, S.R. (1983) *Proc.Natl.Acad.Sci. USA* 80, 7385-7389.
37. Feinberg, A.P. and Vogelstein, B. (1983) *Analytical Biochemistry* 132, 6-13.

38. Mizusawa, S., Nishimura, S. and Seela, F. (1986) *Nucleic Acids Res.* 14, 1319-1324.
39. Sanger, F., Nicklen, S. and Coulson, A.T. (1977) *Proc.Natl. Acad.Sci.USA* 74, 5463-5467.
40. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) *Gene* 33, 103-119.
41. Devereux, J., Haerberli, P. and Smithies, O. (1984) *Nucleic Acids Res.* 12, 387-395.
42. Kanehisa, M. (1984) *Nucleic Acids Res.* 12, 203-213.
43. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) *Molecular Cloning ( Cold Spring Harbor Laboratory )*, 191-193.
44. Thomas, P.S. (1983) In Wu, R., Grossman, L. and Moldave, K. (eds), *Methods in Enzymology*, Academic Press, New York, Vol 100, pp.255-266.
45. Southern, E. (1975) *J.Mol.Biol.* 98, 503-517.
46. Majello, B., Kenyon, L.C. and Dalla-Favera, R. (1986) *Proc. Natl.Acad.Sci. USA.* 83, 9636-9640.
47. Slamon, D.J., Boone, T.C., Murdock, D.C., Keith, D.E., Press, M.F., Larson, R.A. and Souza, L.N. (1986) *Science* 233, 347-351.
48. Katzen, A.L., Kornberg, T.B. and Bishop, J.M. (1985) *Cell* 41, 449-456.
49. Javier, P.-A., Ghosal, D., Wienand, U., Peterson, P.A. and Saedler, H. (1987) *EMBO J.* 6, 3553-3558.
50. Kozak, M. (1984) *Nucleic Acids Res* 12, 857-872.
51. Franza, B.R.Jr., Rauscher III, F.J., Josephs, S.F. and Curran, T. (1988) *Science* 239, 1150-1153.
52. Angel, P., Allehretto, E.A., Okino, S.T., Hattori, K., Boyle, W.J., Hunter, T. and Karin, M. (1988) *Nature (London)* 332, 166-171.
53. Bohmann, D., Bos, T.J., Admon, A., Nishimura, T., Vogt, P.K. and Tjian, R. (1987) *Science* 238, 1386-1392.